Sexual dysfunction in women with systemic autoimmune rheumatic disorders: a systematic review and meta-analysis
Authors' conclusion
Sexual function in females with SARDs seems to be severely impaired, irrespective of the type of SARD.
Study context
- Population
- Women diagnosed with systemic autoimmune rheumatic diseases (SARDs) (mean age 43.7 [12.9] years); PubMed, EMBASE, CENTRAL and grey literature until February 2022
- Participants
- 5,457 women68 studies
- Outcome
- Prevalence of sexual dysfunction (SD) and pooled Female Sexual Function Index (FSFI) scores
Methodological detailsrandom-effects meta-analysis of proportions, double arcsine transformation, Hoy Risk of Bias tool, subgroup and sensitivity analyses, meta-regression
- Random-effects meta-analysis of proportions
- Double arcsine transformation
- Hoy Risk of Bias tool
- Subgroup and sensitivity analyses
- Meta-regression
Pooled result
As reported in the abstract
Overall SD prevalence
63%
95% CI 56, 69%, I2 = 94%
Overall Female Sexual Function Index (FSFI) total score, points
19.7
95% CI 18.4, 21, I2 = 97%
Further pooled results
Sexually active females only
- SD prevalence
- 60% (95% CI: 53, 67%, I2 = 88%)
- FSFI total score, points
- 22 (95% CI: 20.8, 23.1, I2 = 93%)
SD prevalence by SARD (highest levels)
- Sjögren's syndrome
- 74% (95% CI: 58, 87%, I2 = 84%)
- SSc
- 69% (95% CI: 54, 83%, I2 = 94%)
Original publication
Sexual dysfunction in women with systemic autoimmune rheumatic disorders: a systematic review and meta-analysis. Rheumatology (Oxford). Published 11 August 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →